0HI3 Stock Overview
Develops medicines for the treatment of intractable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.41 |
| 52 Week High | US$39.79 |
| 52 Week Low | US$17.24 |
| Beta | 0.93 |
| 11 Month Change | -7.58% |
| 3 Month Change | -26.22% |
| 1 Year Change | -37.45% |
| 33 Year Change | -74.36% |
| 5 Year Change | -74.27% |
| Change since IPO | 200.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HI3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.8% | 0.3% | 2.2% |
| 1Y | -37.4% | -18.3% | 8.0% |
Return vs Industry: 0HI3 underperformed the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0HI3 underperformed the UK Market which returned 8% over the past year.
Price Volatility
| 0HI3 volatility | |
|---|---|
| 0HI3 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HI3 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HI3's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| 0HI3 fundamental statistics | |
|---|---|
| Market cap | US$2.30b |
| Earnings (TTM) | -US$538.64m |
| Revenue (TTM) | US$19.65m |
117.3x
P/S Ratio-4.3x
P/E RatioIs 0HI3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HI3 income statement (TTM) | |
|---|---|
| Revenue | US$19.65m |
| Cost of Revenue | US$0 |
| Gross Profit | US$19.65m |
| Other Expenses | US$558.28m |
| Earnings | -US$538.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -4.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,741.43% |
| Debt/Equity Ratio | 99.1% |
How did 0HI3 perform over the long term?
See historical performance and comparison